Neuraminidase inhibition contributes to influenza A virus neutralization by anti-hemagglutinin stem antibodies. 2019

Ivan Kosik, and Davide Angeletti, and James S Gibbs, and Matthew Angel, and Kazuyo Takeda, and Martina Kosikova, and Vinod Nair, and Heather D Hickman, and Hang Xie, and Christopher B Brooke, and Jonathan W Yewdell
Cellular Biology Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD.

Broadly neutralizing antibodies (Abs) that bind the influenza virus hemagglutinin (HA) stem may enable universal influenza vaccination. Here, we show that anti-stem Abs sterically inhibit viral neuraminidase (NA) activity against large substrates, with activity inversely proportional to the length of the fibrous NA stalk that supports the enzymatic domain. By modulating NA stalk length in recombinant IAVs, we show that anti-stem Abs inhibit virus release from infected cells by blocking NA, accounting for their in vitro neutralization activity. NA inhibition contributes to anti-stem Ab protection in influenza-infected mice, likely due at least in part to NA-mediated inhibition of FcγR-dependent activation of innate immune cells by Ab bound to virions. Food and Drug Administration-approved NA inhibitors enhance anti-stem-based Fc-dependent immune cell activation, raising the possibility of therapeutic synergy between NA inhibitors and anti-stem mAb treatment in humans.

UI MeSH Term Description Entries
D007113 Immunity, Innate The capacity of a normal organism to remain unaffected by microorganisms and their toxins. It results from the presence of naturally occurring ANTI-INFECTIVE AGENTS, constitutional factors such as BODY TEMPERATURE and immediate acting immune cells such as NATURAL KILLER CELLS. Immunity, Native,Immunity, Natural,Immunity, Non-Specific,Resistance, Natural,Innate Immune Response,Innate Immunity,Immune Response, Innate,Immune Responses, Innate,Immunity, Non Specific,Innate Immune Responses,Native Immunity,Natural Immunity,Natural Resistance,Non-Specific Immunity
D009439 Neuraminidase An enzyme that catalyzes the hydrolysis of alpha-2,3, alpha-2,6-, and alpha-2,8-glycosidic linkages (at a decreasing rate, respectively) of terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid, and synthetic substrate. (From Enzyme Nomenclature, 1992) Sialidase,Exo-alpha-Sialidase,N-Acylneuraminate Glycohydrolases,Oligosaccharide Sialidase,Exo alpha Sialidase,Glycohydrolases, N-Acylneuraminate,N Acylneuraminate Glycohydrolases,Sialidase, Oligosaccharide
D009976 Orthomyxoviridae Infections Virus diseases caused by the ORTHOMYXOVIRIDAE. Orthomyxovirus Infections,Infections, Orthomyxoviridae,Infections, Orthomyxovirus,Swine Influenza,Infection, Orthomyxoviridae,Infection, Orthomyxovirus,Influenza, Swine,Orthomyxoviridae Infection,Orthomyxovirus Infection
D009980 Influenza A virus The type species of the genus ALPHAINFLUENZAVIRUS that causes influenza and other diseases in humans and animals. Antigenic variation occurs frequently between strains, allowing classification into subtypes and variants. Transmission is usually by aerosol (human and most non-aquatic hosts) or waterborne (ducks). Infected birds shed the virus in their saliva, nasal secretions, and feces. Alphainfluenzavirus influenzae,Avian Orthomyxovirus Type A,FLUAV,Fowl Plague Virus,Human Influenza A Virus,Influenza Virus Type A,Influenza Viruses Type A,Myxovirus influenzae-A hominis,Myxovirus influenzae-A suis,Myxovirus pestis galli,Orthomyxovirus Type A,Orthomyxovirus Type A, Avian,Orthomyxovirus Type A, Human,Orthomyxovirus Type A, Porcine,Pestis galli Myxovirus,Fowl Plague Viruses,Influenza A viruses,Myxovirus influenzae A hominis,Myxovirus influenzae A suis,Myxovirus, Pestis galli,Myxoviruses, Pestis galli,Pestis galli Myxoviruses,Plague Virus, Fowl,Virus, Fowl Plague
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D005260 Female Females
D000072417 Protein Domains Discrete protein structural units that may fold independently of the rest of the protein and have their own functions. Peptide Domain,Protein Domain,Domain, Peptide,Domain, Protein,Domains, Peptide,Domains, Protein,Peptide Domains
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D017452 Receptors, IgG Specific molecular sites on the surface of various cells, including B-lymphocytes and macrophages, that combine with IMMUNOGLOBULIN Gs. Three subclasses exist: Fc gamma RI (the CD64 antigen, a low affinity receptor), Fc gamma RII (the CD32 antigen, a high affinity receptor), and Fc gamma RIII (the CD16 antigen, a low affinity receptor). Antigens, CD16,Antigens, CD32,Antigens, CD64,CD16 Antigens,CD32 Antigens,CD64 Antigen,CD64 Antigens,Fc Gamma Receptor,Fc Receptors, gamma,Fc gamma Receptors,IgG Receptor,IgG Receptors,Leu-11 Antigen,Receptors, Fc gamma,gamma Fc Receptor,gamma Fc Receptors,CD 16 Antigens,CD 32 Antigens,CD 64 Antigens,CDw32 Antigens,Fc gamma RI,Fc gamma RII,Fc gamma RIII,Immunoglobulin G Receptor,Leu-11 Antigens,Antigen, CD64,Antigen, Leu-11,Antigens, CD 16,Antigens, CD 32,Antigens, CD 64,Antigens, CDw32,Antigens, Leu-11,Fc Receptor, gamma,Gamma Receptor, Fc,Leu 11 Antigen,Leu 11 Antigens,Receptor, Fc Gamma,Receptor, IgG,Receptor, Immunoglobulin G,Receptor, gamma Fc,Receptors, gamma Fc,gamma RI, Fc,gamma RII, Fc,gamma RIII, Fc,gamma Receptors, Fc

Related Publications

Ivan Kosik, and Davide Angeletti, and James S Gibbs, and Matthew Angel, and Kazuyo Takeda, and Martina Kosikova, and Vinod Nair, and Heather D Hickman, and Hang Xie, and Christopher B Brooke, and Jonathan W Yewdell
February 1995, Journal of virology,
Ivan Kosik, and Davide Angeletti, and James S Gibbs, and Matthew Angel, and Kazuyo Takeda, and Martina Kosikova, and Vinod Nair, and Heather D Hickman, and Hang Xie, and Christopher B Brooke, and Jonathan W Yewdell
November 2019, Virology journal,
Ivan Kosik, and Davide Angeletti, and James S Gibbs, and Matthew Angel, and Kazuyo Takeda, and Martina Kosikova, and Vinod Nair, and Heather D Hickman, and Hang Xie, and Christopher B Brooke, and Jonathan W Yewdell
August 1984, Journal of virology,
Ivan Kosik, and Davide Angeletti, and James S Gibbs, and Matthew Angel, and Kazuyo Takeda, and Martina Kosikova, and Vinod Nair, and Heather D Hickman, and Hang Xie, and Christopher B Brooke, and Jonathan W Yewdell
July 1973, Infection and immunity,
Ivan Kosik, and Davide Angeletti, and James S Gibbs, and Matthew Angel, and Kazuyo Takeda, and Martina Kosikova, and Vinod Nair, and Heather D Hickman, and Hang Xie, and Christopher B Brooke, and Jonathan W Yewdell
February 2019, Journal of virology,
Ivan Kosik, and Davide Angeletti, and James S Gibbs, and Matthew Angel, and Kazuyo Takeda, and Martina Kosikova, and Vinod Nair, and Heather D Hickman, and Hang Xie, and Christopher B Brooke, and Jonathan W Yewdell
September 1984, Virology,
Ivan Kosik, and Davide Angeletti, and James S Gibbs, and Matthew Angel, and Kazuyo Takeda, and Martina Kosikova, and Vinod Nair, and Heather D Hickman, and Hang Xie, and Christopher B Brooke, and Jonathan W Yewdell
May 2022, Journal of medicinal chemistry,
Ivan Kosik, and Davide Angeletti, and James S Gibbs, and Matthew Angel, and Kazuyo Takeda, and Martina Kosikova, and Vinod Nair, and Heather D Hickman, and Hang Xie, and Christopher B Brooke, and Jonathan W Yewdell
November 2015, Methods (San Diego, Calif.),
Ivan Kosik, and Davide Angeletti, and James S Gibbs, and Matthew Angel, and Kazuyo Takeda, and Martina Kosikova, and Vinod Nair, and Heather D Hickman, and Hang Xie, and Christopher B Brooke, and Jonathan W Yewdell
November 2017, Biochemical and biophysical research communications,
Ivan Kosik, and Davide Angeletti, and James S Gibbs, and Matthew Angel, and Kazuyo Takeda, and Martina Kosikova, and Vinod Nair, and Heather D Hickman, and Hang Xie, and Christopher B Brooke, and Jonathan W Yewdell
January 2019, Journal of virology,
Copied contents to your clipboard!